Abstract
Several non-coding microRNAs (miRs) are implicated in the pathogenesis of obesity, metabolic syndrome, diabetes mellitus, atherosclerosis and cardiovascular disease. Some of these miRs are beneficial but others are hazardous. Silencing of the latter by antisense oligonucleotides has been attempted in animal models with promising results. However, the replacement of down-regulated beneficial miRs, by manufactured miR mimics, or increasing their expression is much more demanding and has several limitations. The treatment of cardiovascular diseases through miR manipulation shows potential, provided safety and cost effectiveness issues are considered carefully before implementation in humans.
Keywords: microRNA, cardiovascular disease, obesity, metabolic syndrome, diabetes, antisense oligonucleotides, silencing, microRNA mimics.
Current Vascular Pharmacology
Title:Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease
Volume: 13 Issue: 3
Author(s): Vasilios G. Athyros, Niki Katsiki and Asterios Karagiannis
Affiliation:
Keywords: microRNA, cardiovascular disease, obesity, metabolic syndrome, diabetes, antisense oligonucleotides, silencing, microRNA mimics.
Abstract: Several non-coding microRNAs (miRs) are implicated in the pathogenesis of obesity, metabolic syndrome, diabetes mellitus, atherosclerosis and cardiovascular disease. Some of these miRs are beneficial but others are hazardous. Silencing of the latter by antisense oligonucleotides has been attempted in animal models with promising results. However, the replacement of down-regulated beneficial miRs, by manufactured miR mimics, or increasing their expression is much more demanding and has several limitations. The treatment of cardiovascular diseases through miR manipulation shows potential, provided safety and cost effectiveness issues are considered carefully before implementation in humans.
Export Options
About this article
Cite this article as:
Athyros G. Vasilios, Katsiki Niki and Karagiannis Asterios, Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease, Current Vascular Pharmacology 2015; 13 (3) . https://dx.doi.org/10.2174/157016111303150707103801
DOI https://dx.doi.org/10.2174/157016111303150707103801 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insulin Releasing Properties of the Temporin Family of Antimicrobial Peptides
Protein & Peptide Letters Inflammation Theories in Psychotic Disorders: A Critical Review
Infectious Disorders - Drug Targets The Renin-Angiotensin System: New Insight into Old Therapies
Current Medicinal Chemistry S100A1: Structure, Function, and Therapeutic Potential
Current Chemical Biology Tuberculosis: Challenges to Improve the Treatment
Current Clinical Pharmacology Angiotensin-Converting Enzyme Inhibitors in Veterinary Medicine
Current Pharmaceutical Design Diabetic Neuropathy: Update on Pathophysiological Mechanism and the Possible Involvement of Glutamate Pathways
Current Diabetes Reviews Polyglutamine and Neurodegeneration: Structural Aspects
Protein & Peptide Letters Effect of Vitamin D<sub>3</sub> on Lifespan in Caenorhabditis elegans
Current Aging Science Stroke Prevention: From Available Antiplatelet Drugs to Novel Molecular Targets
Current Drug Targets From Biomarkers to Cytokine-like Hormones: Uncovering New Directives for Cognitive Loss and Alzheimer’s Disease
Current Neurovascular Research Emerging Advances in Nanomedicine as a Nanoscale Pharmacotherapy in Rheumatoid Arthritis: State of the Art
Current Topics in Medicinal Chemistry Epigenetics and the Environmental Regulation of the Brain's Genome and its Function
Current Psychiatry Reviews Association of HLA-DRB1 and -DQ Alleles and Haplotypes with Type 1 Diabetes in Jordanians
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Thematic Issue: Therapeutic Applications of Advanced Drug Delivery Systems)
Current Pharmaceutical Design Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Current Clinical Pharmacology Cerebral Arachidonate Cascade in Dementia: Alzheimers Disease and Vascular Dementia
Current Neuropharmacology Cancer and Treatment Modalities
Current Cancer Therapy Reviews Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?
Current Vascular Pharmacology Cannabinoids and Schizophrenia: Therapeutic Prospects
Current Pharmaceutical Design